Therapeutic Area | MeSH |
---|---|
infections | D007239 |
urogenital diseases | D000091642 |
immune system diseases | D007154 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
CABENUVA KIT | ViiV Healthcare | N-212888 RX | 2021-01-21 | 2 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
JULUCA | ViiV Healthcare | N-210192 RX | 2017-11-21 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ODEFSEY | Gilead Sciences | N-208351 RX | 2016-03-01 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
COMPLERA | Gilead Sciences | N-202123 RX | 2011-08-10 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
EDURANT | Johnson & Johnson | N-202022 RX | 2011-05-20 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
cabenuva | New Drug Application | 2023-12-13 |
complera | New Drug Application | 2020-12-09 |
complera access | Export only | 2020-12-10 |
juluca | New Drug Application | 2022-10-07 |
odefsey | New Drug Application | 2020-12-15 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
hiv infections | EFO_0000764 | D015658 | B20 |
Expiration | Code | ||
---|---|---|---|
CABOTEGRAVIR / RILPIVIRINE, CABENUVA KIT, VIIV HLTHCARE | |||
2026-01-21 | NCE | ||
2025-03-29 | NPP | ||
2025-01-31 | D-184 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Emtricitabine / Rilpivirine Hydrochloride / Tenofovir Disoproxil Fumarate, Complera, Gilead Sciences Inc | |||
10857102 | 2033-01-14 | DP | |
8841310 | 2025-12-09 | DP | U-257 |
8592397 | 2024-01-13 | DP | U-257 |
8716264 | 2024-01-13 | DP | U-257 |
9457036 | 2024-01-13 | DP | U-257 |
9744181 | 2024-01-13 | DP | U-257 |
Emtricitabine / Rilpivirine Hydrochloride / Tenofovir Alafenamide Fumarate, Odefsey, Gilead Sciences Inc | |||
8754065 | 2032-08-15 | DS, DP | U-257 |
9296769 | 2032-08-15 | DS, DP | U-257 |
7390791 | 2025-04-17 | DS, DP | |
Cabotegravir / Rilpivirine, Cabenuva Kit, Viiv Hlthcare | |||
11224597 | 2031-09-15 | DP | U-3348 |
11389447 | 2027-06-30 | U-3405 | |
8410103 | 2026-04-28 | DS, DP | U-3348 |
10927129 | 2026-04-28 | DS, DP | |
7125879 | 2025-04-21 | DS, DP | U-257, U-1153, U-1307, U-1740, U-3348, U-3353 |
Dolutegravir Sodium / Rilpivirine Hydrochloride, Juluca, Viiv Hlthcare | |||
10426780 | 2031-01-24 | DS, DP | U-257 |
9242986 | 2029-12-08 | DS, DP | |
8129385 | 2027-10-05 | DS, DP |
Code | Description |
---|---|
J0741 | Injection, cabotegravir and rilpivirine, 2mg/3mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | 14 | 14 | 38 | 10 | 15 | 83 |
Hiv | D006678 | — | O98.7 | 7 | 4 | 8 | 4 | 10 | 31 |
Hiv-1 | D015497 | — | — | 3 | 3 | 2 | 1 | — | 9 |
Healthy volunteers/patients | — | — | — | 6 | — | — | 2 | — | 8 |
Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | — | — | 1 | — | 1 |
Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | — | 1 | — | 1 |
Patient compliance | D010349 | — | — | — | — | — | 1 | — | 1 |
Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | 1 | — | 1 |
Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | — | 1 | — | 1 |
Hiv-associated lipodystrophy syndrome | D039682 | EFO_1001348 | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Infections | D007239 | EFO_0000544 | — | 4 | 2 | 1 | — | — | 7 |
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 2 | 1 | 2 | — | 1 | 5 |
Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | — | 2 | — | 1 | 3 |
Hepatitis c | D006526 | — | B19.2 | 1 | — | 1 | — | — | 2 |
Glycogen storage disease type ii | D006009 | Orphanet_365 | E74.02 | — | — | 1 | — | — | 1 |
Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Contraception | D003267 | — | — | — | 2 | — | — | 1 | 3 |
Hiv-2 | D015498 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hepacivirus | D016174 | — | — | 2 | — | — | — | — | 2 |
Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Insulin resistance | D007333 | HP_0000855 | E88.819 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | — | — | — | — | 1 | 1 |
Dyslipidemias | D050171 | HP_0003119 | — | — | — | — | — | 1 | 1 |
Sustained virologic response | D000072230 | — | — | — | — | — | — | 1 | 1 |
Drug interactions | D004347 | — | — | — | — | — | — | 1 | 1 |
Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 1 | 1 |
Disease progression | D018450 | — | — | — | — | — | — | 1 | 1 |
Medication adherence | D055118 | EFO_0006344 | — | — | — | — | — | 1 | 1 |
Patient satisfaction | D017060 | — | — | — | — | — | — | 1 | 1 |
Patient preference | D057240 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Rilpivirine |
INN | rilpivirine |
Description | Rilpivirine is an aminopyrimidine that is pyrimidine-2,4-diamine in which the amino groups at positions 2 and 4 are substituted by 4-cyanophenyl and 4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl groups respectively. Used for treatment of HIV. It has a role as a HIV-1 reverse transcriptase inhibitor and an EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor. It is a nitrile and an aminopyrimidine. It is a conjugate base of a rilpivirine(1+). |
Classification | Small molecule |
Drug class | antivirals: non-nucleoside reverse transcriptase inhibitors, not benzoxazinone derivatives |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1 |
PDB | — |
CAS-ID | 500287-72-9 |
RxCUI | — |
ChEMBL ID | CHEMBL175691 |
ChEBI ID | 68606 |
PubChem CID | 6451164 |
DrugBank | DB08864 |
UNII ID | FI96A8X663 (ChemIDplus, GSRS) |